Our top pick for
Building a portfolio
Bellerophon Therapeutics, Inc is a biotechnology business based in the US. Bellerophon Therapeutics shares (BLPH) are listed on the NASDAQ and all prices are listed in US Dollars. Bellerophon Therapeutics employs 21 staff and has a market cap (total outstanding shares value) of USD$47.7 million.
|52-week range||USD$4.9244 - USD$20.68|
|50-day moving average||USD$6.3591|
|200-day moving average||USD$7.6744|
|Wall St. target price||USD$23.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.085|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Bellerophon Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bellerophon Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bellerophon Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 5x. In other words, Bellerophon Therapeutics shares trade at around 5x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Gross profit TTM||USD$0|
|Return on assets TTM||-41.39%|
|Return on equity TTM||-118.2%|
|Market capitalisation||USD$47.7 million|
TTM: trailing 12 months
There are currently 307,745 Bellerophon Therapeutics shares held short by investors – that's known as Bellerophon Therapeutics's "short interest". This figure is 3% up from 298,705 last month.
There are a few different ways that this level of interest in shorting Bellerophon Therapeutics shares can be evaluated.
Bellerophon Therapeutics's "short interest ratio" (SIR) is the quantity of Bellerophon Therapeutics shares currently shorted divided by the average quantity of Bellerophon Therapeutics shares traded daily (recently around 91590.773809524). Bellerophon Therapeutics's SIR currently stands at 3.36. In other words for every 100,000 Bellerophon Therapeutics shares traded daily on the market, roughly 3360 shares are currently held short.
However Bellerophon Therapeutics's short interest can also be evaluated against the total number of Bellerophon Therapeutics shares, or, against the total number of tradable Bellerophon Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bellerophon Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Bellerophon Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0409% of the tradable shares (for every 100,000 tradable Bellerophon Therapeutics shares, roughly 41 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bellerophon Therapeutics.
Find out more about how you can short Bellerophon Therapeutics stock.
We're not expecting Bellerophon Therapeutics to pay a dividend over the next 12 months.
Bellerophon Therapeutics's shares were split on a 1:15 basis on 9 February 2020. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Bellerophon Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Bellerophon Therapeutics shares which in turn could have impacted Bellerophon Therapeutics's share price.
Over the last 12 months, Bellerophon Therapeutics's shares have ranged in value from as little as $4.9244 up to $20.68. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bellerophon Therapeutics's is -0.5295. This would suggest that Bellerophon Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Bellerophon Therapeutics has bucked the trend.
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.